Skip to main content
SpringerLink
Log in
Book cover

Extravasation of Cytotoxic Agents pp 195–212Cite as

Doxorubicin

  • Chapter

  • 977 Accesses

Abstract

1. Stop injection/infusion immediately

2. Get extravasation kit

3. Put on (sterile) gloves

4. Replace infusion lead or syringe with 5 ml disposable syringe and aspirate slowly as much as possible of the extravasated drug; Cave! do not exert pressure on extravasation area

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Original articles

  1. Bhawan J, Petry J, Rybak ME: Histologic changes induced in skin by extravasation of doxorubicin (adriamycin). J Cutan Pathol 16: 158–163, 1989.

    Article  PubMed  CAS  Google Scholar 

  2. Bowers DG, Lynch JB: Adriamycin extravasation. Plast Reconstr Surg 61: 86–92, 1978.

    Article  PubMed  Google Scholar 

  3. Köstering H, Kasten U, Ruskowski H, et al: Lokale Toxizität des Adriamycins. In: Füllenbach D, et al (eds) Beiträge zur Onkologie. S. Karger 9: 76–93, 1981.

    Google Scholar 

  4. Larson DL: What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 75: 397–402, 1985.

    Article  PubMed  CAS  Google Scholar 

  5. Reilly JJ, Neifeld JP, Rosenberg SA: Clinical course and management of accidental adriamycin extravasation. Cancer 40: 2053–2056, 1977.

    Article  PubMed  CAS  Google Scholar 

  6. Rudolph R, Stein RS, Pattillo RA: Skin ulcers due to adriamycin. Cancer 38: 1087–1094, 1976.

    Article  PubMed  CAS  Google Scholar 

  7. Linder RM, Upton J, Osteen R: Management of extensive doxorubicin hydrochloride extravasation injuries. J Hand Surg 8: 32–38, 1983.

    CAS  Google Scholar 

  8. Rudolph R: Ulcers of the hand and wrist caused by doxorubicin hydrochloride. Orthop Rev 7: 93–95, 1978.

    Google Scholar 

  9. Lauvin R, Miglianico L, Hellegouarc’h R: Skin cancer occurring 10 years after the extravasation of doxorubicin. N Engl J Med 332: 754, 1995.

    Article  PubMed  CAS  Google Scholar 

  10. Lawrence HJ, Walsh D, Zapotowski KA, et al: Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation. Cancer Chemother Pharmacol 23: 316–318, 1989.

    Article  PubMed  CAS  Google Scholar 

  11. Tsavaris NB, Karagiaouris P, Tzannou I, et al: Conservative approach to the treatment of chemotherapy-induced extravasation. J Dermatol Surg Oncol 16: 519–522, 1990.

    PubMed  CAS  Google Scholar 

  12. Tsavaris NB, Komitsopoulou P, Karagiaouris P, et al: Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 30: 330–333, 1992.

    Article  PubMed  CAS  Google Scholar 

  13. Comas D, Mateu J: Treatment of extravasation of both doxorubicin and vincristine administration in a y-site infusion. Ann -Pharmacother 30: 244–246, 1996.

    PubMed  CAS  Google Scholar 

  14. Ludwig CU, Stoll HR, Obrist R, et al: Prevention of cytotoxic drug induced skin ulcers with dimethyl sulfoxide (DMSO) and a-tocopherole. Eur J Cancer Clin Oncol 23: 327–329, 1987.

    Article  PubMed  CAS  Google Scholar 

  15. Bertelli G, Dini D, Forno G, et al: Dimethylsulphoxide and cooling after extravasation of antitumour agents. Lancet 341: 1098–1099, 1993.

    Article  PubMed  CAS  Google Scholar 

  16. Bertelli G, Gozza A, Forno GB, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851–2855, 1995.

    PubMed  CAS  Google Scholar 

  17. Olver IN, Schwarz MA: Use of dimethyl sulfoxide in limiting tissue damage caused by extravasation of doxorubicin. Cancer Treat Rep 67: 407–408, 1983.

    PubMed  CAS  Google Scholar 

  18. Olver IN, Aisner J, Hament A, et al: A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 6: 1732–1735, 1988.

    PubMed  CAS  Google Scholar 

  19. Zweig JI, Kabakow B: An apparently effective countermeasure for doxorubicin extravasation. JAMA 239: 2116, 1978.

    Article  PubMed  CAS  Google Scholar 

  20. Scuderi N, Onesti MG: Antitumor agents: extravasation, management, and surgical treatment. Ann Plast Surg 32: 39–44, 1994.

    Article  PubMed  CAS  Google Scholar 

  21. Heckler FR: Current thoughts of extravasation injuries. Clin Plast Surg 16: 557–563, 1989.

    PubMed  CAS  Google Scholar 

  22. Jackson IT, Robinson DW: Severe tissue damage following accidental subcutaneous infusion of bicarbonate solution. Scot Med J 21: 200–201, 1976.

    PubMed  CAS  Google Scholar 

  23. Gaze NR: Tissue necrosis caused by commonly used intravenous infusions. Lancet 2: 417–419, 1978.

    Article  PubMed  CAS  Google Scholar 

  24. Kappel B, Hindenburg AA, Taub RN: Treatment of anthracycline extravasation – a warning against the use of sodium bicarbonate. J Clin Oncol 5: 825–826, 1987.

    PubMed  CAS  Google Scholar 

  25. Cohen MH: Amelioration of adriamycin skin necrosis: an experimental study. Cancer Treat Rep 63: 1003–1004, 1979.

    PubMed  CAS  Google Scholar 

  26. Luedke DW, Kennedy PS, Rietschel RL: Histopathogenesis of skin and subcutaneous injury induced by adriamycin. Plast Reconstr Surg 63: 463–465, 1979.

    Article  PubMed  CAS  Google Scholar 

  27. Dorr RT, Alberts DS, Chen HS: The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse. Cancer Chemother Pharmacol 5: 17–20, 1980.

    Article  PubMed  CAS  Google Scholar 

  28. Coleman JJ, Walker AP, Didolkar MS: Treatment of adriamycin-induced skin ulcers: a prospective controlled study. J Surg Oncol 22: 129–135, 1983.

    Article  PubMed  CAS  Google Scholar 

  29. Petro JA, Graham WP, Miller SH, et al: Experimental and clinical studies of ulcers induced with adriamycin. Surg Forum 30: 535–537, 1979.

    PubMed  CAS  Google Scholar 

  30. Cohen SC, DiBella NJ, Michalak JC: Recall injury from adriamycin. Ann Intern Med 83: 232, 1975.

    Article  PubMed  CAS  Google Scholar 

  31. Etcubanas E, Wilbur JR: Uncommon side effects of adriamycin (NSC-123127). Cancer Chemother Rep 58: 757–758, 1974.

    PubMed  CAS  Google Scholar 

  32. Ostrowski MJ: An unusual allergic reaction in a vein following intravenous adriamycin. Clin Oncol 2: 179–180, 1976.

    PubMed  CAS  Google Scholar 

  33. Souhami L, Feld R: Urticaria following intravenous doxorubicin administration. JAMA 240: 1624–1626, 1978.

    Article  PubMed  CAS  Google Scholar 

  34. Dorr RT, Alberts DS: Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compounds. Cancer Treat Rep 65: 1001–1006, 1981.

    PubMed  CAS  Google Scholar 

  35. Sonneveld P, Wassenaar HA, Nooter K: Long persistence of doxorubicin in human skin after extravasation. Cancer Treat Rep 68: 895–896, 1984.

    PubMed  CAS  Google Scholar 

  36. Pitkänen J, Asko-Seljavaara S, Gröhn P, et al: Adriamycin extravasation: surgical treatment and possible prevention of skin and soft-tissue injuries. J Surg Oncol 23: 259–262, 1983.

    Article  PubMed  Google Scholar 

  37. Barlock AL, Howser DM, Hubbard SM: Nursing management of adriamycin extravasation. Am J Nurs 79: 94–96, 1979.

    PubMed  CAS  Google Scholar 

  38. Germain BS, Houlihan N, D´Amato S: Dimethyl sulfoxide therapy in the treatment of vesicant extravasation. J Intrav Nurs 17: 261–266, 1994.

    Google Scholar 

  39. Bartkowski-Dodds L, Daniels JR: Use of sodium bicarbonate as a means of ameliorating doxorubicin-induced dermal necrosis in rats. Cancer Chemother Pharmacol 4: 179–181, 1980.

    Article  PubMed  CAS  Google Scholar 

  40. Harwood K, Gonin R: Short term vs. long term local cooling after doxorubicin (DOX) extravasation: an eastern cooperative oncology group (ECOG) study. Proc ASCO 13: 447 (abstract 1544), 1994.

    Google Scholar 

  41. Nobbs P, Barr RD: Soft-tissue injury caused by antineoplastic drugs is inhibited by topical dimethyl sulphoxide and alpha tocopherol. Br J Cancer 48: 873–876, 1983.

    Article  PubMed  CAS  Google Scholar 

  42. Emiroglu M, Ercöcen AR, Demirseren ME, et al: Histopathological changes in adriamycin extravasation injury. Ann Plast Surg 41: 103–104, 1998.

    Article  PubMed  CAS  Google Scholar 

  43. Cohen FJ, Manganaro J, Bezozo RC: Identification of involved -tissue during surgical treatment of doxorubicin-induced extravasation necrosis. J Hand Surg 8: 43–45, 1983.

    CAS  Google Scholar 

  44. Averbuch SD, Gaudiano G, Koch TH, et al: Doxorubicin-induced skin necrosis in the swine model: protection with a novel radical dimer. J Clin Oncol 4: 88–94, 1986.

    PubMed  CAS  Google Scholar 

  45. Vasilev SA, Morrow C, Morrow CP: Basic fibroblast growth factor in retardation of doxorubicin extravasation injury. Gynecol Oncol 44: 178–181, 1992.

    Article  PubMed  CAS  Google Scholar 

  46. Kahn MS, Holmes JD: Reducing the morbidity from extravasation injuries. Ann Plast Surg 48: 628–632, 2002.

    Article  Google Scholar 

  47. Whang SW, Lee SH, Elias PM, et al: Intralesional steroids reduce inflammation from extravasated chemotherapeutic agents. Br J Dermatol 145: 680–682, 2001.

    Article  PubMed  CAS  Google Scholar 

  48. Mouridsen HT, Langer SW, Buter J, et al: Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective cilinical multicentre studies. Ann Oncol 18: 546–550, 2007.

    Article  PubMed  CAS  Google Scholar 

  49. Parikh PM, Ranjan S, Swami A, et al: Phlogenzym® is safe and effective in reducing morbidity of vesicant chemotherapy extravasation. A prospective study. Int J Immunother 17: 163–170, 2001.

    CAS  Google Scholar 

  50. El Shagir N, Otrock Z, Mufarrij A, et al: Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol 5: 320–321, 2004.

    Article  Google Scholar 

  51. Schrijvers DL: Extravasation: a dreaded complication of chemotherapy. Ann Oncol 14: iii26–iii30, 2003.

    PubMed  Google Scholar 

  52. Langer SW, Sehested M, Jensen PB: Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 6: 3680–3686, 2000.

    PubMed  CAS  Google Scholar 

  53. Langer SW, Sehested M, Jensen PB: Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol 12: 405–410, 2001.

    Article  PubMed  CAS  Google Scholar 

  54. Askar I, Erbas MK, Gurlek A: Effects of heparin fractions on the prevention of skin necrosis resulting from adriamycin extravasation: an experimental study. Ann Plast Surg 49: 297–301, 2002.

    Article  PubMed  Google Scholar 

  55. Disa JJ, Chang RR, Mucci SJ, et al: Prevention of adriamycin-induced fullthickness skin loss using hyaluronidase infiltration. Plast Reconstr Surg 101: 370–374, 1998.

    Article  PubMed  CAS  Google Scholar 

  56. Spugnini EP: Use of hyaluronidase for the treatment of extravasation of chemotherapeutic agents in six dogs. JAVMA 221: 1437–1440, 2002.

    Article  PubMed  CAS  Google Scholar 

  57. Eroglu E, Sari A, Altuntas I, et al: The effect of GM-CSF -(granulocyte macrophage colony stimulating factor) on doxorubicin-induced tissue necrosis and wound healing. Indian J Cancer 37: 153–157, 2000.

    CAS  Google Scholar 

  58. Vargel I, Erdem A, Ertoy D, et al: Effects of growth factors on doxorubicin induced skin necrosis: documentation of histomorphological alteration and early treatment by GM-CSF. Ann Plast Surg 49: 646–653, 2002.

    Article  PubMed  Google Scholar 

  59. Ultin HC, Guden M, Dede M, et al: Comparison of granulocyte-colony stimulating factor and granulocyte macrophage-colonystimulating factor in the treatment of chemnotherapy extravasation ulcers. Eur J Gynaecol Oncol 21: 613–615, 2000.

    Google Scholar 

  60. Atkas S, Toklu AS, Olgyc V: Hyperbaric oxygen therapy in adriamycin extravasation: a experimental animal study. Ann Plast Surg 45: 167–171, 2000.

    Article  Google Scholar 

  61. Monstrey SJ, Mullick P, Naranyanan K, et al: Hyperbaric oxygen therapy and free radical production: a experimental study in doxorubicin (adriamycin) extravasation injuries. Ann Plast Surg 36: 163–168, 1997.]

    Article  Google Scholar 

Secondary literature

  1. Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.

    Article  PubMed  CAS  Google Scholar 

  2. Köstering H, Nagel GA: Prophylaxe und Therapie von Zytostatika-Hautnekrosen. Onkologie 6: 317–320, 1980.

    Google Scholar 

  3. Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.

    Article  PubMed  CAS  Google Scholar 

  4. Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.

    Google Scholar 

  5. Stanley A: Managing complications of chemotherapy administration. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 119–193, 2002.

    Google Scholar 

  6. Krämer I, Stützle M: Zytostatika-Paravasation – Wie ist vorzugehen? Krankenhauspharmazie 23: 261–268, 2002.

    Google Scholar 

  7. Gain M, Melzer S, Meyer-Jürshof A, et al: Doxorubicin: Behandlung von Paravasaten: In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 3: 68–69, 1998.

    Google Scholar 

  8. Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.

    Google Scholar 

  9. Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.

    Google Scholar 

  10. Cox RF: Managing skin damage induced by doxorubicin hydrochloride and daunorubicin hydrochloride. Am J Hosp Pharm 41: 2410–2414, 1984.

    PubMed  CAS  Google Scholar 

  11. Rospond RM: Utilization of dimethyl sulfoxide for treating anthracycline extravasation. J Oncol Pharm Practice 1: 33–39, 1995.

    Article  CAS  Google Scholar 

  12. Rudolph R, Larson DL: Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol 5: 1116–1126, 1987.

    PubMed  CAS  Google Scholar 

  13. Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.

    Article  PubMed  CAS  Google Scholar 

  14. Kraft A, Weinig S, Edinger M, et al: Anthrazyklin-Extravasate. Der Onkologe 6: 674–686, 2000.

    Article  Google Scholar 

  15. Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: -Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 1, 2nd edition: A42–44, 1997.

    Google Scholar 

  16. Jordan K, Grothe W, Schmoll HJ: Paravasation von Zytostatika: Prävention und Therapie. Dtsch Med Wochenschr 130: 33–37, 2005.

    Article  PubMed  CAS  Google Scholar 

  17. Ener RA, Meglathery SB, Styler M: Extravasation of systemic hemato-oncological therapies. Ann Oncol 15: 858–862, 2004.

    Article  PubMed  CAS  Google Scholar 

  18. Koppel RA, Boh EE: Cutaneous reactions to chemotherapeutic agents. Am J Med Sci 321: 327–335, 2001.

    Article  PubMed  CAS  Google Scholar 

  19. Alley E, Green R, Schuchter L: Cutaneous toxicities of cancer therapy. Curr Opin Oncol 14: 212–216, 2002.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CRETA – Cancer Research & Trial Agency GmbH, Bad Sauerbrunn, Österreich

    Ines Mader MD

  2. Krankenhaus und Geriatriezentrum, SMZ Floridsdorf, Wien, Österreich

    Mag. pharm. Patrizia Fürst-Weger

  3. Klinische Abteilung für Onkologie, Univ.-Klinik für Innere Medizin I, Wien, Österreich

    Univ.-Prof. Dr. Robert Mader

  4. Anstaltsapotheke, Landeskrankenhaus – Universitätskliniken Innsbruck, Innsbruck, Österreich

    Mag. pharm. Dr. Elisabeth Nogler-Semenitz

  5. Apotheke LKH-Univ.-Klinikum Graz, Graz, Österreich

    Mag. pharm. Sabine Wassertheurer

Authors
  1. Ines Mader MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mag. pharm. Patrizia Fürst-Weger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Univ.-Prof. Dr. Robert Mader
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mag. pharm. Dr. Elisabeth Nogler-Semenitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mag. pharm. Sabine Wassertheurer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag/Wien

About this chapter

Cite this chapter

Mader, I., Fürst-Weger, P., Mader, R., Nogler-Semenitz, E., Wassertheurer, S. (2010). Doxorubicin. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-211-88893-3_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-88893-3_29

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-88889-6

  • Online ISBN: 978-3-211-88893-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation